AI Consulting for Healthcare

It can, but health information is classified as sensitive information under the Privacy Act 1988, which means it attracts the strictest handling requirements in the Act — a higher bar than the customer data most AI vendors design for. In practice that changes four things about a deployment. First, consent and collection notices have to actually describe what happens, including the fact that a third-party system processes the information. Second, Australian Privacy Principle 8 makes you accountable for the information if it is disclosed overseas, so the hosting region of every component matters and "the cloud" is not an answer. Third, APP 11 requires reasonable security steps, which for health data means encryption, access logging and a real answer to who at the vendor can read a record. Fourth, the Notifiable Data Breaches scheme applies, so you need to know in advance how a vendor would support an assessment. We work through those four points as a written record during the audit. To be explicit: we are consultants, not a certification body — we do not certify or guarantee your compliance, and your practice remains the accountable entity.

Our standing advice is to start nowhere near it. Software that is intended to inform clinical decisions can fall within the definition of a medical device and be regulated by the TGA, and clinical decision support is exactly the category where the regulatory obligation, the professional accountability and the harm potential all peak at once. The value available from practice administration is large, immediate and carries a fraction of the risk. Recalls, referrals, intake, phone overflow, correspondence handling and billing queries are all high-volume and low-clinical-stakes. Most practices we speak to have not yet exhausted the administrative opportunity, so there is rarely a good reason to accept clinical risk in a first project. If a genuine clinical use case is on the table later, it needs a separate conversation involving your indemnity insurer, your clinical governance process and, in all likelihood, TGA advice.

They are one of the few AI tools where clinicians report an immediate, felt benefit, because documentation is the part of the day that follows people home. They are also a case where the detail decides everything. The questions that matter: is the patient consenting to being recorded and is that consent recorded; is audio retained or discarded after transcription; where is processing performed and is any of it offshore; is your consultation data used to improve the vendor’s model; and does the clinician review and sign every note before it enters the record? The last one is not negotiable — the note is a clinical record and the clinician remains accountable for its accuracy, no matter how good the draft was. Our role in a scribe decision is usually unglamorous: read the vendor’s contract and data flows properly, pressure-test the answers, and tell you which of the shortlist actually holds up.

It constrains it; it rarely kills it. Australian practices run a wide spread of practice management software, and integration maturity varies enormously — some have well-documented APIs, some have a partner program you must be admitted to, and some have essentially nothing. The audit maps that honestly early, because it changes the whole plan. Where a real API exists, agents can read and write directly and the automation is clean. Where it does not, the workable options are the surrounding systems: your phone line, your inbox, your online forms, your document flow and your reporting exports. A surprising share of practice admin pain lives in those surrounding systems anyway, so a closed PMS is usually a reason to sequence the work differently rather than abandon it. What we will not do is recommend screen-scraping a clinical system or anything else that breaks your vendor agreement.

Take it seriously, because it is a legitimate position and it is also a risk to your reputation if handled badly. Trust in a health service is slow to build and quick to lose, and "we did not tell patients" is the failure mode that generates complaints and media interest, not the technology itself. The practical approach is transparency plus a genuine alternative: say plainly where AI is used, keep a human route available for people who ask for one, and never let a patient discover it by accident. Australian Health Practitioner Regulation Agency guidance and your professional obligations around informed consent and honesty point the same way. In our experience, practices that are upfront about using AI for phones, reminders and paperwork get very little pushback, because patients can see the benefit is a faster answer rather than a cheaper clinician.

It starts with a free initial consultation — a conversation about what is actually breaking, not a demo. If there is a real opportunity and the scale justifies it, the next step is usually the AI Opportunity Audit, a paid engagement at around $3,000 that produces a written map of your workflows, the data and systems behind them, the privacy and regulatory constraints attached to each, and a ranked shortlist of what to do first with realistic effort and payback. That audit is deliberately useful even if you never engage us again — it is yours, including the parts that say do nothing. Where it makes sense, we then build and ship the first workflow into production rather than handing over a slide deck, and we stay involved while it beds in. The audit is generally worth it once a practice is around 20 or more staff; below that the honest advice is often one or two tools and no consultant.